PEP/NEWS — Peptide intel. Daily.

NAD+ LEVELS DECLINE ~50% BETWEEN AGES 40 AND 60 IN HUMAN TISSUE STUDIESCREATINE SUPPLEMENTATION REDUCES MUSCLE LOSS MARKERS BY UP TO 30% IN OVER-60 TRIALSCALORIC RESTRICTION EXTENDS MEDIAN LIFESPAN BY 30-40% IN MULTIPLE RODENT MODELSSENESCENT CELLS CAN COMPRISE UP TO 15% OF TOTAL CELLS IN AGED TISSUEGLP-1 RECEPTOR AGONISTS NOW STUDIED IN OVER 40 ACTIVE LONGEVITY-ADJACENT TRIALS GLOBALLYPLASMA DILUTION STUDIES REPORT UP TO 50% REDUCTION IN PRO-AGING FACTORS IN OLD MICEEPIGENETIC CLOCKS CAN NOW ESTIMATE BIOLOGICAL AGE WITH UNDER 3-YEAR MEDIAN ERRORPARTIAL REPROGRAMMING VIA YAMANAKA FACTORS HAS REVERSED AGE MARKERS IN RETINAL CELLS IN VIVO NAD+ LEVELS DECLINE ~50% BETWEEN AGES 40 AND 60 IN HUMAN TISSUE STUDIESCREATINE SUPPLEMENTATION REDUCES MUSCLE LOSS MARKERS BY UP TO 30% IN OVER-60 TRIALSCALORIC RESTRICTION EXTENDS MEDIAN LIFESPAN BY 30-40% IN MULTIPLE RODENT MODELSSENESCENT CELLS CAN COMPRISE UP TO 15% OF TOTAL CELLS IN AGED TISSUEGLP-1 RECEPTOR AGONISTS NOW STUDIED IN OVER 40 ACTIVE LONGEVITY-ADJACENT TRIALS GLOBALLYPLASMA DILUTION STUDIES REPORT UP TO 50% REDUCTION IN PRO-AGING FACTORS IN OLD MICEEPIGENETIC CLOCKS CAN NOW ESTIMATE BIOLOGICAL AGE WITH UNDER 3-YEAR MEDIAN ERRORPARTIAL REPROGRAMMING VIA YAMANAKA FACTORS HAS REVERSED AGE MARKERS IN RETINAL CELLS IN VIVO
◤ Top story · Peter Attia
PETER ATTIA GOES DEEP ON PEPTIDES: LEGITIMATE SCIENCE VS. THE HYPE MACHINE...

*Attia draws a hard line between peptides with real evidence and those riding the hype wave.*

— Peter Attia

Featured Briefs

◤ Article · Peptide-anchored

PETER ATTIA: NAD+ SUPPLEMENTS, DEMENTIA RISK REDUCTION, AND METABOLIC HEALTH IN ONE AMA...

AMA #84 covers NAD+ supplementation evidence, family cardiovascular history as a risk modifier, and the efficiency math behind strength training — a dense, evidence-anchored session for serious optimizers.

Peter Attia
◤ Article

NATURE: MICROPROTEINS AND PEPTIDEINS EXPAND THE KNOWN HUMAN PROTEOME...

A Nature paper identifies a previously uncharacterized class of small proteins and peptide-like molecules encoded in the human genome — expanding the therapeutic target landscape and raising questions about which of these 'peptideins' may have biological activity worth pursuing.

Nature Briefing

More Headlines